الفهرس 
COVID-19Only 14 pages are availabe for public view
 |  | from | 160 |  |  |
| | | from | 160 | | |
Abstract
Background: Thrombosis and embolism are possible complications in COVID-19-positive pediatric patients. Although the risk is lesser in children than it is in adults, it does exist during acute infection and multiinflammatory syndrome (MIS-C). Biomarkers such as D-dimer, Prothrombin time (PT), and Fibrinogen degradation products (FDPs) are ineffective at detecting disease severity. Homocysteine (Hcy) is a prothrombotic factor that has been reported to be higher in adult COVID-19 patients, leading to speculation that it could be used as a biomarker for disease severity. Purpose: to detect the correlation between serum total homocysteine (tHcy) level and the severity of COVID-19 in pediatrics. Methods: a cross-sectional study was conducted on 40 children with COVID-19 and 40 healthy control subjects. Serum tHcy was measured by ELISA and correlated with the clinical, laboratory, and radiological parameters of the patients. Results: The median serum tHcy level in COVID-19 patients was 27.5 (interquartile range:23 – 31.75) μmol/L, while that in the controls was 1.8 ((interquartile range:1.6 – 1.875) μmol/L. There was a statistically significant increase in tHcy level in cases compared to controls (p<0.001). There was a statistically significant positive correlation between serum tHcy and D- dimer, ferritin, alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and a highly significant positive correlation between tHcy and CO-RADS score, PICU admission, and the disease severity classification. Conclusion: Hcy could be a biomarker of importance in predicting the severity of COVID-19 in pediatrics.